{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:40:11Z","timestamp":1782261611524,"version":"3.54.5"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Enterococcus faecalis (Efc) and Enterococcus faecium (Efm) are frequently resistant to vancomycin and \u03b2-lactams (BLs). In vitro data suggest synergy between several BLs and glycopeptides or lipopeptides against resistant pathogens. Our objective was to conduct combination MIC and time\u2013kill experiments to evaluate BL synergy with daptomycin against enterococci.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Fifteen Efc and 20 Efm strains were evaluated for daptomycin enhancement via combination MICs. Daptomycin MICs were obtained by microdilution in the absence and presence of ceftaroline, ertapenem, cefepime, ceftriaxone, cefotaxime, cefazolin and ampicillin. Two Efc strains (R6981 and R7808) and one isogenic daptomycin-susceptible\/daptomycin-non-susceptible Efm pair (8019\/5938) were evaluated in time\u2013kill experiments. Daptomycin at 0.5\u200a\u00d7\u200aMIC was used in combination with BL at biological free concentration. Strain 5938 was evaluated for enhancement of daptomycin binding in fluorescently labelled daptomycin (BoDipy) experiments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ceftaroline reduced daptomycin MIC values the most against all strains. In time\u2013kill experiments, ceftaroline, ertapenem, cefepime, ceftriaxone and ampicillin demonstrated synergy with daptomycin against all strains, cefazolin demonstrated none and cefotaxime demonstrated synergy against only R7808. Bacterial reduction at 24 h was greater for daptomycin\u200a+\u200aceftaroline, ertapenem, cefepime, ceftriaxone or ampicillin for all strains compared with any single agent or daptomycin\u200a+\u200acefazolin or cefotaxime (P\u200a&amp;lt;\u200a0.001). In BoDipy daptomycin experiments, ceftaroline enhanced daptomycin binding most compared with all other agents (P\u200a&amp;lt;\u200a0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The data support the potential use of daptomycin\/BL combination therapy in infections caused by VRE. Combination regimens, other than those involving cefazolin and cefotaxime, provide better kill compared with daptomycin alone. Further clinical research involving daptomycin combinations is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkv007","type":"journal-article","created":{"date-parts":[[2015,2,3]],"date-time":"2015-02-03T00:06:35Z","timestamp":1422921995000},"page":"1738-1743","source":"Crossref","is-referenced-by-count":121,"title":["\u03b2-Lactam combinations with daptomycin provide synergy against vancomycin-resistant\n                    <i>Enterococcus faecalis<\/i>\n                    and\n                    <i>Enterococcus faecium<\/i>"],"prefix":"10.1093","volume":"70","author":[{"given":"Jordan R.","family":"Smith","sequence":"first","affiliation":[{"name":"1 \u00a0Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie E.","family":"Barber","sequence":"additional","affiliation":[{"name":"1 \u00a0Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Animesh","family":"Raut","sequence":"additional","affiliation":[{"name":"1 \u00a0Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Aboutaleb","sequence":"additional","affiliation":[{"name":"1 \u00a0Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Sakoulas","sequence":"additional","affiliation":[{"name":"2 \u00a0University of California San Diego School of Medicine, La Jolla, CA, USA"},{"name":"3 \u00a0University of California San Diego Division of Biology, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Rybak","sequence":"additional","affiliation":[{"name":"1 \u00a0Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, USA"},{"name":"4 \u00a0Wayne State University School of Medicine, \u00a0Detroit, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,2,1]]},"reference":[{"key":"2022020123411485000_DKV007C1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/668770","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009\u20132010","volume":"34","author":"Sievert","year":"2013","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2022020123411485000_DKV007C2","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.syapm.2012.05.004","article-title":"Antibiotic resistance and virulence traits in clinical and environmental Enterococcus faecalis and Enterococcus faecium isolates","volume":"35","author":"Rathnayake","year":"2012","journal-title":"Syst Appl Microbiol"},{"key":"2022020123411485000_DKV007C3","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1086\/661599","article-title":"Growing prevalence of vancomycin-resistant Enterococcus faecalis in the region with the highest prevalence of vancomycin-resistant Staphylococcus aureus","volume":"32","author":"Hayakawa","year":"2011","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2022020123411485000_DKV007C4","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ijid.2014.02.012","article-title":"Incidence, risk factors, and outcomes of Enterococcus spp. blood stream infections: a population-based study","volume":"26","author":"Billington","year":"2014","journal-title":"Int J Infect Dis"},{"key":"2022020123411485000_DKV007C5","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1001\/archinte.162.19.2223","article-title":"Health and economic outcomes of vancomycin-resistant enterococci","volume":"162","author":"Carmeli","year":"2002","journal-title":"Arch Intern Med"},{"key":"2022020123411485000_DKV007C6","first-page":"e394","article-title":"Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America","volume":"111","author":"Baddour","year":"2005","journal-title":"Circulation"},{"key":"2022020123411485000_DKV007C7","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1128\/AAC.00526-13","article-title":"Multicenter study of high-dose daptomycin for treatment of enterococcal infections","volume":"57","author":"Casapao","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020123411485000_DKV007C8","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1128\/CMR.00030-13","article-title":"A current perspective on daptomycin for the clinical microbiologist","volume":"26","author":"Humphries","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"2022020123411485000_DKV007C9","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1128\/AAC.45.2.454-459.2001","article-title":"Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations","volume":"45","author":"Akins","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020123411485000_DKV007C10","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1128\/AAC.06439-11","article-title":"Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic\/pharmacodynamic model with simulated endocardial vegetations","volume":"56","author":"Hall","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020123411485000_DKV007C11","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1093\/jac\/dkt294","article-title":"A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis","volume":"68","author":"Kullar","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2022020123411485000_DKV007C12","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ijantimicag.2014.01.018","article-title":"Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: summary of 8 years of a Worldwide Surveillance Programme (2005\u20132012)","volume":"43","author":"Sader","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2022020123411485000_DKV007C13","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing: Twenty-second Informational Supplement M100-S22","author":"Clinical and Laboratory Standards Institute","year":"2012"},{"key":"2022020123411485000_DKV007C14","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.diagmicrobio.2013.11.011","article-title":"Prevalence of antibiotic resistance in US hospitals","volume":"78","author":"Edelsberg","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2022020123411485000_DKV007C15","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.diagmicrobio.2012.11.024","article-title":"Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011)","volume":"75","author":"Jones","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2022020123411485000_DKV007C16","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1128\/AAC.00509-12","article-title":"Correlation between mutations in liaFSR of Enterococcus faecium and MIC of daptomycin: revisiting daptomycin breakpoints","volume":"56","author":"Munita","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020123411485000_DKV007C17","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1128\/AAC.02274-13","article-title":"Ceftaroline restores daptomycin activity against daptomycin-nonsusceptible vancomycin-resistant Enterococcus faecium","volume":"58","author":"Sakoulas","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020123411485000_DKV007C18","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1093\/jac\/dku113","article-title":"Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic\/pharmacodynamic simulated endocardial vegetation model","volume":"69","author":"Hall Snyder","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020123411485000_DKV007C19","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1128\/AAC.05551-11","article-title":"Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium","volume":"56","author":"Sakoulas","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020123411485000_DKV007C20","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1128\/AAC.02481-12","article-title":"Treatment of high-level gentamicin-resistant Enterococcus faecalis endocarditis with daptomycin plus ceftaroline","volume":"57","author":"Sakoulas","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020123411485000_DKV007C21","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1128\/AAC.01760-12","article-title":"Combination therapy with ampicillin and daptomycin for treatment of Enterococcus faecalis endocarditis","volume":"56","author":"Sierra-Hoffman","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020123411485000_DKV007C22","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1128\/AAC.01318-12","article-title":"Genotypic and phenotypic evaluation of the evolution of high-level daptomycin nonsusceptibility in vancomycin-resistant Enterococcus faecium","volume":"56","author":"Humphries","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020123411485000_DKV007C23","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1046\/j.1365-2958.1999.01255.x","article-title":"A vital stain for studying membrane dynamics in bacteria: a novel mechanism controlling septation during Bacillus subtilis sporulation","volume":"31","author":"Pogliano","year":"1999","journal-title":"Mol Microbiol"},{"key":"2022020123411485000_DKV007C24","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1128\/AAC.45.5.1480-1486.2001","article-title":"Penicillin-binding protein 5 and expression of ampicillin resistance in Enterococcus faecium","volume":"45","author":"Rice","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020123411485000_DKV007C25","doi-asserted-by":"crossref","first-page":"6358","DOI":"10.1128\/AAC.00923-13","article-title":"Activity of ceftaroline against Enterococcus faecium PBP5","volume":"57","author":"Henry","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020123411485000_DKV007C26","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1128\/AAC.39.9.1984","article-title":"Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis","volume":"39","author":"Mainardi","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020123411485000_DKV007C27","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/cid\/cit052","article-title":"Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating Enterococcus faecalis infective endocarditis","volume":"56","author":"Fernandez-Hidalgo","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2022020123411485000_DKV007C28","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ijantimicag.2014.03.011","article-title":"In vitro synergy of ampicillin with gentamicin, ceftriaxone and ciprofloxacin against Enterococcus faecalis","volume":"44","author":"Liao","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2022020123411485000_DKV007C29","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.1128\/AAC.02686-14","article-title":"Whole genome analyses of Enterococcus faecium with diverse daptomycin minimal inhibitory concentrations","volume":"58","author":"Diaz","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020123411485000_DKV007C30","doi-asserted-by":"crossref","first-page":"e00281","DOI":"10.1128\/mBio.00281-13","article-title":"Daptomycin-resistant Enterococcus faecalis diverts the antibiotic molecule from the division septum and remodels cell membrane phospholipids","volume":"4","author":"Tran","year":"2013","journal-title":"mBio"},{"key":"2022020123411485000_DKV007C31","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1517\/13543784.10.6.1157","article-title":"Ertapenem: a new carbapenem","volume":"10","author":"Odenholt","year":"2001","journal-title":"Expert Opin Investig Drugs"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/70\/6\/1738\/42358409\/jac_70_6_1738.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/70\/6\/1738\/42358409\/jac_70_6_1738.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T18:42:26Z","timestamp":1643740946000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/70\/6\/1738\/728283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,1]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2015,2,1]]},"published-print":{"date-parts":[[2015,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkv007","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725339727.793540652","asserted-by":"object"}]},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2015,6]]},"published":{"date-parts":[[2015,2,1]]}}}